Asset
Atebimetinib
Immuneering Corporation Class A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05585320 | phase1_2 | active_not_recruiting | 2022-10-31 | 2026-06-01 | Immuneering Corporation | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors |
| NCT07562152 | phase3 | recruiting | 2026-06-05 | 2028-06-01 | Immuneering Corporation | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
FDA applications (0)
This company has no applications containing this asset.